Cover Image
Market Research Report

Asia Pacific Immunosuppressant Drugs Market Forecast 2019-2028

Published by Inkwood Research Product code 939706
Published Content info 104 Pages
Delivery time: 2-3 business days
Price
Back to Top
Asia Pacific Immunosuppressant Drugs Market Forecast 2019-2028
Published: June 1, 2020 Content info: 104 Pages
Description

KEY FINDINGS

The Asia Pacific immunosuppressant drugs market is projected to register a CAGR of 5.51% during the forecast period, 2019-2028. The rising per capita income in several countries of the region, government initiatives for the enhancement of the healthcare sector, the presence of leading manufacturers, and their activities for extending geographical presence, are the most important factors driving the market growth.

MARKET INSIGHTS

The Asia Pacific immunosuppressant drugs market growth analysis encompasses the market evaluation of Japan, Indonesia, China, Thailand, Vietnam, India, Australia & New Zealand, South Korea, and the rest of Asia Pacific. There is a growing demand for organ translation, and a rise in autoimmune diseases like irritable bowel syndrome and arthritis, which impacts market growth in the region. In Japan, the drugs for immunosuppressive agents and diabetes are registering strong growth, and is set to witness more growth propelled by novel biologics. India has placed itself in a prominent position in global pharmaceuticals. It is a major contributor to generic medicines globally, ranking third in the world for production by volume. The country accounts for almost 15% of the world's production by value. The country houses more than 3000 pharma companies, along with being home to several autoimmune diseases. India has an emboldened living kidney transplantation program, second to the USA. Such factors make the country a conducive market in terms of growth prospects.

COMPETITIVE INSIGHTS

Some of the well-established companies of the market include, Sanofi SA, Dr. Reddy's Laboratories Ltd, Cipla Ltd, Pfizer Inc, Mylan NV, Novartis International Ag (Sandoz), etc.

Our report offerings include:

  • Explore key findings of the overall market
  • Strategic breakdown of market dynamics (Drivers, Restraints, Opportunities, Challenges)
  • Market forecasts for a minimum of 9 years, along with 3 years of historical data for all segments, sub-segments, and regions
  • Market Segmentation cater to a thorough assessment of key segments with their market estimations
  • Geographical Analysis: Assessments of the mentioned regions and country-level segments with their market share
  • Key analytics: Porter's Five Forces Analysis, Vendor Landscape, Opportunity Matrix, Key Buying Criteria, etc.
  • Competitive landscape is the theoretical explanation of the key companies based on factors, market share, etc.
  • Company profiling: A detailed company overview, product/services offered, SCOT analysis, and recent strategic developments
Table of Contents
Product Code: 31803

TABLE OF CONTENTS

1. RESEARCH SCOPE & METHODOLOGY

  • 1.1. STUDY OBJECTIVES
  • 1.2. SCOPE OF STUDY
  • 1.3. METHODOLOGY
  • 1.4. ASSUMPTIONS & LIMITATIONS

2. EXECUTIVE SUMMARY

  • 2.1. MARKET SIZE & ESTIMATES
  • 2.2. MARKET OVERVIEW

3. MARKET DYNAMICS

  • 3.1. DEVELOPMENT OF IMMUNOSUPPRESSANT DRUGS
  • 3.2. MARKET DEFINITION
  • 3.3. KEY DRIVERS
    • 3.3.1. INCREASE IN THE NUMBER OF AUTOIMMUNE DISORDERS
    • 3.3.2. RISE IN ORGAN TRANSPLANTATION
    • 3.3.3. GROWTH IN THE PHARMACEUTICAL INDUSTRY
  • 3.4. KEY RESTRAINTS
    • 3.4.1. SIDE EFFECTS OF IMMUNOSUPPRESSANT DRUGS
    • 3.4.2. LACK OF AWARENESS ABOUT ORGAN DONATION

4. KEY ANALYTICS

  • 4.1. KEY INVESTMENT INSIGHTS
  • 4.2. PORTER'S FIVE FORCE ANALYSIS
    • 4.2.1. BUYER POWER
    • 4.2.2. SUPPLIER POWER
    • 4.2.3. SUBSTITUTION
    • 4.2.4. NEW ENTRANTS
    • 4.2.5. INDUSTRY RIVALRY
  • 4.3. OPPORTUNITY MATRIX
  • 4.4. VENDOR LANDSCAPE

5. MARKET BY DISTRIBUTION CHANNEL

  • 5.1. HOSPITAL PHARMACIES
  • 5.2. RETAIL PHARMACIES
  • 5.3. ONLINE PHARMACIES

6. MARKET BY END-USER

  • 6.1. ORGAN TRANSPLANTATION
  • 6.2. AUTOIMMUNE DISORDERS
  • 6.3. OTHERS

7. MARKET BY DRUG CLASS

  • 7.1. CORTICOSTEROIDS
  • 7.2. MONOCLONAL ANTIBODIES
  • 7.3. CALCINEURIN INHIBITORS
  • 7.4. MTOR INHIBITORS
  • 7.5. OTHERS

8. GEOGRAPHICAL ANALYSIS

  • 8.1. ASIA PACIFIC
    • 8.1.1. CHINA
    • 8.1.2. JAPAN
    • 8.1.3. INDIA
    • 8.1.4. SOUTH KOREA
    • 8.1.5. INDONESIA
    • 8.1.6. THAILAND
    • 8.1.7. VIETNAM
    • 8.1.8. AUSTRALIA & NEW ZEALAND
    • 8.1.9. REST OF ASIA PACIFIC

9. COMPANY PROFILES

  • 9.1. ABBVIE INC
  • 9.2. ALLERGAN PLC (ACQUIRED BY ABVIE INC)
  • 9.3. ASTELLAS PHARMA INC
  • 9.4. BRISTOL-MYERS SQUIBB COMPANY
  • 9.5. CIPLA LTD
  • 9.6. DR. REDDY'S LABORATORIES LTD
  • 9.7. F HOFFMANN-LA ROCHE AG
  • 9.8. GLAXOSMITHKLINE PLC
  • 9.9. INTAS PHARMACEUTICALS LTD (ACCORD HEALTHCARE LTD)
  • 9.10. JANSSEN PHARMACEUTICALS NV (JHONSON & JHONSON)
  • 9.11. MYLAN NV
  • 9.12. NOVARTIS INTERNATIONAL AG (SANDOZ)
  • 9.13. PFIZER INC
  • 9.14. SANOFI SA
  • 9.15. VELOXIS PHARMACEUTICALS

LIST OF TABLES

  • TABLE 1: MARKET SNAPSHOT - IMMUNOSUPPRESSANT DRUGS
  • TABLE 2: SIDE EFFECTS OF IMMUNOSUPPRESSANT DRUGS
  • TABLE 3: TOP 15 POSITIVE NET EXPORTS COUNTRIES AND NEGATIVE NET EXPORTS FOR DRUGS & MEDICINES COUNTRIES
  • TABLE 4: ASIA PACIFIC IMMUNOSUPPRESSANT DRUGS MARKET, BY DISTRIBUTION CHANNEL, HISTORICAL YEARS, 2016-2019 (IN $ MILLION)
  • TABLE 5: ASIA PACIFIC IMMUNOSUPPRESSANT DRUGS MARKET, BY DISTRIBUTION CHANNEL, FORECAST YEARS, 2019-2028 (IN $ MILLION)
  • TABLE 6: ASIA PACIFIC IMMUNOSUPPRESSANT DRUGS MARKET, BY END-USER, HISTORICAL YEARS, 2016-2019 (IN $ MILLION)
  • TABLE 7: ASIA PACIFIC IMMUNOSUPPRESSANT DRUGS MARKET, BY END-USER, FORECAST YEARS, 2019-2028 (IN $ MILLION)
  • TABLE 8: ASIA PACIFIC IMMUNOSUPPRESSANT DRUGS MARKET, BY CLASS, HISTORICAL YEARS, 2016-2019 (IN $ MILLION)
  • TABLE 9: ASIA PACIFIC IMMUNOSUPPRESSANT DRUGS MARKET, BY CLASS, FORECAST YEARS, 2019-2028 (IN $ MILLION)
  • TABLE 10: ASIA PACIFIC IMMUNOSUPPRESSANT DRUGS MARKET, BY COUNTRY, HISTORICAL YEARS, 2016-2019 (IN $ MILLION)
  • TABLE 11: ASIA PACIFIC IMMUNOSUPPRESSANT DRUGS MARKET, BY COUNTRY, FORECAST YEARS, 2019-2028 (IN $ MILLION)

LIST OF FIGURES

  • FIGURE 1: DEVELOPMENT OF IMMUNOSUPPRESSANT DRUGS
  • FIGURE 2: KEY INVESTMENT INSIGHTS
  • FIGURE 3: PORTER'S FIVE FORCE ANALYSIS
  • FIGURE 4: OPPORTUNITY MATRIX
  • FIGURE 5: VENDOR LANDSCAPE
  • FIGURE 6: ASIA PACIFIC IMMUNOSUPPRESSANT DRUGS MARKET, GROWTH POTENTIAL, BY DISTRIBUTION CHANNEL, IN 2019
  • FIGURE 7: ASIA PACIFIC IMMUNOSUPPRESSANT DRUGS MARKET, BY HOSPITAL PHARMACIES, 2019-2028 (IN $ MILLION)
  • FIGURE 8: ASIA PACIFIC IMMUNOSUPPRESSANT DRUGS MARKET, BY RETAIL PHARMACIES, 2019-2028 (IN $ MILLION)
  • FIGURE 9: ASIA PACIFIC IMMUNOSUPPRESSANT DRUGS MARKET, BY ONLINE PHARMACIES, 2019-2028 (IN $ MILLION)
  • FIGURE 10: ASIA PACIFIC IMMUNOSUPPRESSANT DRUGS MARKET, GROWTH POTENTIAL, BY END-USER, IN 2019
  • FIGURE 11: ASIA PACIFIC IMMUNOSUPPRESSANT DRUGS MARKET, BY ORGAN TRANSPLANTATION, 2019-2028 (IN $ MILLION)
  • FIGURE 12: ASIA PACIFIC IMMUNOSUPPRESSANT DRUGS MARKET, BY AUTOIMMUNE DISORDERS, 2019-2028 (IN $ MILLION)
  • FIGURE 13: ASIA PACIFIC IMMUNOSUPPRESSANT DRUGS MARKET, BY OTHERS, 2019-2028 (IN $ MILLION)
  • FIGURE 14: ASIA PACIFIC IMMUNOSUPPRESSANT DRUGS MARKET, GROWTH POTENTIAL, BY CLASS, IN 2019
  • FIGURE 15: ASIA PACIFIC IMMUNOSUPPRESSANT DRUGS MARKET, BY CORTICOSTEROIDS, 2019-2028 (IN $ MILLION)
  • FIGURE 16: ASIA PACIFIC IMMUNOSUPPRESSANT DRUGS MARKET, BY MONOCLONAL ANTIBODIES, 2019-2028 (IN $ MILLION)
  • FIGURE 17: ASIA PACIFIC IMMUNOSUPPRESSANT DRUGS MARKET, BY CALCINEURIN INHIBITORS, 2019-2028 (IN $ MILLION)
  • FIGURE 18: ASIA PACIFIC IMMUNOSUPPRESSANT DRUGS MARKET, BY MTOR INHIBITORS, 2019-2028 (IN $ MILLION)
  • FIGURE 19: ASIA PACIFIC IMMUNOSUPPRESSANT DRUGS MARKET, BY OTHERS, 2019-2028 (IN $ MILLION)
  • FIGURE 20: ASIA PACIFIC IMMUNOSUPPRESSANT DRUGS MARKET, REGIONAL OUTLOOK, 2019 & 2028 (IN %)
  • FIGURE 21: CHINA IMMUNOSUPPRESSANT DRUGS MARKET, 2019-2028 (IN $ MILLION)
  • FIGURE 22: JAPAN IMMUNOSUPPRESSANT DRUGS MARKET, 2019-2028 (IN $ MILLION)
  • FIGURE 23: INDIA IMMUNOSUPPRESSANT DRUGS MARKET, 2019-2028 (IN $ MILLION)
  • FIGURE 24: SOUTH KOREA IMMUNOSUPPRESSANT DRUGS MARKET, 2019-2028 (IN $ MILLION)
  • FIGURE 25: INDONESIA IMMUNOSUPPRESSANT DRUGS MARKET, 2019-2028 (IN $ MILLION)
  • FIGURE 26: THAILAND IMMUNOSUPPRESSANT DRUGS MARKET, 2019-2028 (IN $ MILLION)
  • FIGURE 27: VIETNAM IMMUNOSUPPRESSANT DRUGS MARKET, 2019-2028 (IN $ MILLION)
  • FIGURE 28: AUSTRALIA & NEW ZEALAND IMMUNOSUPPRESSANT DRUGS MARKET, 2019-2028 (IN $ MILLION)
  • FIGURE 29: REST OF ASIA PACIFIC IMMUNOSUPPRESSANT DRUGS MARKET, 2019-2028 (IN $ MILLION)
Back to Top